BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1093 related articles for article (PubMed ID: 27427982)

  • 1. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape.
    Hegde M; Mukherjee M; Grada Z; Pignata A; Landi D; Navai SA; Wakefield A; Fousek K; Bielamowicz K; Chow KK; Brawley VS; Byrd TT; Krebs S; Gottschalk S; Wels WS; Baker ML; Dotti G; Mamonkin M; Brenner MK; Orange JS; Ahmed N
    J Clin Invest; 2016 Aug; 126(8):3036-52. PubMed ID: 27427982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.
    Krenciute G; Prinzing BL; Yi Z; Wu MF; Liu H; Dotti G; Balyasnikova IV; Gottschalk S
    Cancer Immunol Res; 2017 Jul; 5(7):571-581. PubMed ID: 28550091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study.
    Kim K; Gwak HS; Han N; Hong EK; Choi BK; Lee S; Choi S; Park JH; Seok JH; Jeon Y; Cho H; Lee SJ; Lee Y; Nam KT; Song SW
    Front Immunol; 2021; 12():715000. PubMed ID: 34819930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma.
    Hegde M; Corder A; Chow KK; Mukherjee M; Ashoori A; Kew Y; Zhang YJ; Baskin DS; Merchant FA; Brawley VS; Byrd TT; Krebs S; Wu MF; Liu H; Heslop HE; Gottschalk S; Yvon E; Ahmed N
    Mol Ther; 2013 Nov; 21(11):2087-101. PubMed ID: 23939024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
    Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
    Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.
    Brown CE; Aguilar B; Starr R; Yang X; Chang WC; Weng L; Chang B; Sarkissian A; Brito A; Sanchez JF; Ostberg JR; D'Apuzzo M; Badie B; Barish ME; Forman SJ
    Mol Ther; 2018 Jan; 26(1):31-44. PubMed ID: 29103912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spatial organization of heterogeneous immunotherapy target antigen expression in high-grade glioma.
    Barish ME; Weng L; Awabdeh D; Zhai Y; Starr R; D'Apuzzo M; Rockne RC; Li H; Badie B; Forman SJ; Brown CE
    Neoplasia; 2022 Aug; 30():100801. PubMed ID: 35550513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma.
    Bielamowicz K; Fousek K; Byrd TT; Samaha H; Mukherjee M; Aware N; Wu MF; Orange JS; Sumazin P; Man TK; Joseph SK; Hegde M; Ahmed N
    Neuro Oncol; 2018 Mar; 20(4):506-518. PubMed ID: 29016929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel TanCAR targeting IL13Rα2 and EphA2 for enhanced glioblastoma therapy.
    Muhammad N; Wang R; Li W; Zhang Z; Chang Y; Hu Y; Zhao J; Zheng X; Mao Q; Xia H
    Mol Ther Oncolytics; 2022 Mar; 24():729-741. PubMed ID: 35317513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma.
    Krenciute G; Krebs S; Torres D; Wu MF; Liu H; Dotti G; Li XN; Lesniak MS; Balyasnikova IV; Gottschalk S
    Mol Ther; 2016 Feb; 24(2):354-363. PubMed ID: 26514825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cells redirected to interleukin-13Rα2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1.
    Krebs S; Chow KK; Yi Z; Rodriguez-Cruz T; Hegde M; Gerken C; Ahmed N; Gottschalk S
    Cytotherapy; 2014 Aug; 16(8):1121-31. PubMed ID: 24841514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL13Rα2-targeted third-generation CAR-T cells with CD28 transmembrane domain mediate the best anti-glioblastoma efficacy.
    Gu A; Bai Y; Zhang C; Xu C; An Z; Zhang Y; Zhong SH; Hu Y; Zhong X
    Cancer Immunol Immunother; 2023 Jul; 72(7):2393-2403. PubMed ID: 36991262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors.
    Yang M; Tang X; Zhang Z; Gu L; Wei H; Zhao S; Zhong K; Mu M; Huang C; Jiang C; Xu J; Guo G; Zhou L; Tong A
    Theranostics; 2020; 10(17):7622-7634. PubMed ID: 32685008
    [No Abstract]   [Full Text] [Related]  

  • 14. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.
    Brown CE; Badie B; Barish ME; Weng L; Ostberg JR; Chang WC; Naranjo A; Starr R; Wagner J; Wright C; Zhai Y; Bading JR; Ressler JA; Portnow J; D'Apuzzo M; Forman SJ; Jensen MC
    Clin Cancer Res; 2015 Sep; 21(18):4062-72. PubMed ID: 26059190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inclusion of 4-1BB Costimulation Enhances Selectivity and Functionality of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells.
    Starr R; Aguilar B; Gumber D; Maker M; Huard S; Wang D; Chang WC; Brito A; Chiu V; Ostberg JR; Badie B; Forman SJ; Alizadeh D; Wang LD; Brown CE
    Cancer Res Commun; 2023 Jan; 3(1):66-79. PubMed ID: 36968221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells.
    Kong S; Sengupta S; Tyler B; Bais AJ; Ma Q; Doucette S; Zhou J; Sahin A; Carter BS; Brem H; Junghans RP; Sampath P
    Clin Cancer Res; 2012 Nov; 18(21):5949-60. PubMed ID: 22966020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.
    Kahlon KS; Brown C; Cooper LJ; Raubitschek A; Forman SJ; Jensen MC
    Cancer Res; 2004 Dec; 64(24):9160-6. PubMed ID: 15604287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and Production An Effective Bispecific Tandem Chimeric Antigen Receptor on T Cells against CD123 and Folate Receptor ß towards B-Acute Myeloid Leukaemia Blasts.
    Ghamari A; Pakzad P; Majd A; Ebrahimi M; Hamidieh AA
    Cell J; 2021 Nov; 23(6):650-657. PubMed ID: 34939758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres.
    Nehama D; Di Ianni N; Musio S; Du H; Patané M; Pollo B; Finocchiaro G; Park JJH; Dunn DE; Edwards DS; Damrauer JS; Hudson H; Floyd SR; Ferrone S; Savoldo B; Pellegatta S; Dotti G
    EBioMedicine; 2019 Sep; 47():33-43. PubMed ID: 31466914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineered IL13 variants direct specificity of IL13Rα2-targeted CAR T cell therapy.
    Stern LA; Gholamin S; Moraga I; Yang X; Saravanakumar S; Cohen JR; Starr R; Aguilar B; Salvary V; Hibbard JC; Kalbasi A; Shepphird JK; O'Hearn J; Garcia KC; Brown CE
    Proc Natl Acad Sci U S A; 2022 Aug; 119(33):e2112006119. PubMed ID: 35939683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.